From Ancestry to Bioanarchy: How 23andMe’s DNA Became Regeneron’s Drug-Fuel

In the latest episode of “Big Pharma Meets Your Gummy Swab,” drug titan Regeneron Pharmaceuticals scooped up 23andMe at a bankruptcy auction for a cool $256 million, promising to “respect your privacy” while mining your spit for the next blockbuster drug. 

Cue the collective exhale from 15 million genetic adventurers who once dreamed their cheek swab would reveal Viking blood or a mysterious Neanderthal cousin—only to learn it now funds the creation of high-priced biologics.

Chapter 11 Swab-athon

When 23andMe slid into Chapter 11 bankruptcy in March, bankruptcy court watchers swarmed like taxonomists at a rare species sighting. 

A court-appointed overseer is set to ensure Regeneron sticks to 23andMe’s original privacy pledge, because nothing says “trust us” like a pharma behemoth promising to uphold your swabbed secrets.

Privacy: More Than a Buzzword

Regeneron’s Senior Vice President and Head of the Regeneron Genetics Center insists the company will “prioritize the privacy, security, and ethical use” of your DNA data—faster than you can say “data breach.” 

After last October’s breach exposed 6.9 million customers’ genetic info, those words might feel like a soothing placebo. But as every clinical trial begins with “informed consent,” so too does this acquisition—though “informed” sometimes means “in the fine print.”

Business as (Un)usual

23andMe will persist as your go-to ancestry narrator, delivering quips like “You’re 0.02% Sardinian!” while Regeneron gleans which genes spark the next LDL-lowering monoclonal antibody. 

Meanwhile, the Chair of the Special Committee of the Board of Directors beams that this deal “maximizes value” and keeps 23andMe’s mission alive—albeit with more pipettes and lab coats than at grandma’s house.

Employee Lifeboats

In a kinder twist, Regeneron extended job offers to 23andMe staffers from impacted departments—because nothing says “we value you” like reassigning your lab bench to a new corporate floor plan. 

Some analysts predict this infusion of pureed genomes will turbocharge drug pipelines, while privacy advocates warn we’ve just turned our spit stash into a “genomic gold mine.”

What’s Next?

Pending final bankruptcy and regulatory sign-offs, the deal should close in Q3. 

Then, get ready for the era of “precision medicine” where your ancestry report might read: “10% Scandinavian, 90% potential blockbuster drug target.”

So, keep swabbing, dear genome jockeys—because your next holiday card might come stamped from Regeneron’s R&D wing: “Season’s Greetings… and a side of CRISPR!”

23andMe’s Bankruptcy Breakup and the “Delete Your DNA” Ultimatum 

 

Please support my writing by donating $1 at https://buymeacoffee.com/doublejeopardynews

 

---

1. #SwabAndSell

2. #GenomicGoldMine

3. #PharmaPays256M

4. #PrivacyPlease

5. #AncestryToAntibodies

6. #Chapter11CheekSwabs

7. #DataBreachRedux

8. #DrugDiscoverySpit

9. #RegeneronR&D

10. #GeneticGoldRush

11. #SpitLabSpinoff

12. #Bioanarchy

13. #SwabSellsOut

14. #FinePrintFrenzy

15. #CRISPRChristmas